However, Phase 1 and Phase 2 clinical trial data indicated elevated transaminase enzyme levels, indicating the potential for liver dysfunction
If nausea becomes problematic at this dose, discuss management strategies with your provider
It has become an increasingly recognized option in medical weight management because of its ability to support appetite regulation and metabolic balance
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
, 131 , 356-369, doi: Wu, Z., Geng, Y., Lu, X., Shi, Y., Wu, G., Zhang, M., Shan, B., Pan, H., and Yuan, J